Long non-coding RNAs may serve as biomarkers in breast cancer combined with primary lung cancer
Metrics: PDF 1590 views | HTML 1866 views | ?
Xianfeng Ding1,*, Yuhan Zhang1,*, Hongjian Yang2,*, Weimin Mao3, Bo Chen4, Shifeng Yang4, Xiaowen Ding2, Dehong Zou2, Wenju Mo2, Xiangming He2 and Xiping Zhang2
1College of Life Science, Zhejiang Sci-Tech University, Hangzhou 310008, Zhejiang Province, China
2Department of Breast Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China
3Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China
4Department of Pathology, Zhejiang Cancer Hospital, Hangzhou 310022, Zhejiang Province, China
*These authors contributed equally to this work
Xiping Zhang, email: email@example.com
Keywords: lncRNA, breast cancer combined with primary lung cancer, biomarkers
Received: December 28, 2016 Accepted: April 07, 2017 Published: April 21, 2017
Long non-coding RNAs (lncRNAs) have been shown to play important regulatory role in certain type of cancers biology, including breast and lung cancers. However, the lncRNA expression in breast cancer combined with primary lung cancer remains unknown. In this study, databases of the Cancer Genome Atlas (TCGA) and the lncRNA profiler of contained candidate 192 lncRNAs were utilized. 11 lncRNAs were differentially expressed in breast cancer, 9 candidate lncRNAs were differentially expressed in lung cancer. In order to find the aberrant expression of lncRNAs in breast cancer combined with primary lung cancer, seven samples of primary breast cancer and lung cancer were studied for the expression of selected lncRNAs. The results showed that SNHG6 and NEAT1 were reversely expressed in breast cancer combined with primary lung cancer compared with primary breast or lung cancer. In addition, a significant correlation of lncRNAs was found in the patients whose age was above 56 in breast cancer. What’s more, PVT1 expression was negatively correlated with the pathological stage, and the level of ER, PR, HER2, p53 in breast cancer. Furthermore, lncRNA expression did not have significant relationship with the 5-year survival of patients with breast cancer combined with primary lung cancer. The findings revealed that PVT1, SNHG6, NEAT1 may serve as a prognostic marker for breast cancer combined with primary lung cancer. Therefore, these lncRNAs are potential molecular indicators in the diagnosis and prognosis of cancer in the future.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.